On Monday, Heron Therapeutics Inc (NASDAQ: HRTX) was 2.04% up from the session before settling in for the closing price of $2.45. A 52-week range for HRTX has been $0.50 – $3.22.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 17.85% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 71.29%. With a float of $142.66 million, this company’s outstanding shares have now reached $150.29 million.
In an organization with 126 employees, it is important to assess its efficiency.
Heron Therapeutics Inc (HRTX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Heron Therapeutics Inc stocks. The insider ownership of Heron Therapeutics Inc is 5.10%, while institutional ownership is 71.10%. The most recent insider transaction that took place on Nov 17 ’23, was worth 27,250. In this transaction EVP, Chief Development Officer of this company bought 25,000 shares at a rate of $1.09, taking the stock ownership to the 79,000 shares. Before that another transaction happened on Nov 16 ’23, when Company’s Chief Executive Officer bought 150,000 for $0.92, making the entire transaction worth $137,970. This insider now owns 186,496 shares in total.
Heron Therapeutics Inc (HRTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 71.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.50% during the next five years compared to 20.01% growth over the previous five years of trading.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
You can see what Heron Therapeutics Inc (HRTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Let’s dig in a bit further. During the last 5-days, its volume was 3.02 million. That was better than the volume of 2.77 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 14.13%. Additionally, its Average True Range was 0.21.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 61.29%, which indicates a significant increase from 7.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.91% in the past 14 days, which was lower than the 86.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.73, while its 200-day Moving Average is $1.80. However, in the short run, Heron Therapeutics Inc’s stock first resistance to watch stands at $2.55. Second resistance stands at $2.60. The third major resistance level sits at $2.65. If the price goes on to break the first support level at $2.45, it is likely to go to the next support level at $2.40. Assuming the price breaks the second support level, the third support level stands at $2.35.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
There are 150,329K outstanding shares of the company, which has a market capitalization of 375.83 million. As of now, sales total 127,040 K while income totals -110,560 K. Its latest quarter income was 34,230 K while its last quarter net income were -10,720 K.
